Trial Profile

A phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of BBP-398 in combination with LUMAKRAS in patients with advanced solid tumors with the KRAS G12C mutation

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 14 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Oct 2022 According to a BridgeBio Pharma media release, Initial data of this study is expected by the end of 2024.
11 Oct 2022 Status changed from planning to recruiting, according to a BridgeBio Pharma media release.
11 Oct 2022 According to a BridgeBio Pharma media release, company announced that the first patient with non-small cell lung cancer (NSCLC) has been dosed in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com